Apatinib for Advanced Lung Squmamous Carcinoma

Sponsor
Xuzhou Central Hospital
Study ID
NCT03725423
Phase
PHASE4
Status
Unknown

Conditions

  • Lung Squamous Cell Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    250mg, qd once a day, take it half an hour after meal (the time for taking the medicine should be the same as possible), and take it with warm water. 28 days is a drug delivery cycle.

Study Details

In order to search for effective and low toxicity anti-tumor angiogenesis drugs, jiangsu hengrui pharmaceutical co., ltd. developed the high-efficiency VEGFR2 tyrosine kinase inhibitor apatinib. This drug is mainly used to treat malignant tumors by inhibiting VEGFR2 to play an anti-angiogenic role. Both in vivo and in vitro experiments have shown that apatinib has good tumor growth inhibition activity for lung cancer. This study aims to further confirm the effectiveness and safety of apatinib third-line treatment for patients with advanced lung squamous cell carcinoma.

Key Dates

Start date
Oct 31, 2018
Status verified
Oct 2018
Primary completion
Jun 30, 2019
Completion
Jun 30, 2019

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: experimental group
    Oral administration of 250mg of apatinib daily, with or without chemotherapy

Primary Outcome Measure

Respond Evaluation Criteria in Solid Tumors [ Time Frame: Through study completion,an average of 1 year ]

Central Contacts

Related Studies